Premium
Autologous T lymphocytes recognize the tumour‐derived immunoglobulin VH‐CDR3 region in patients with B‐cell chronic lymphocytic leukaemia
Author(s) -
Rezvany Mohammad Reza,
JeddiTehrani Mahmood,
Rabbani Hodjattallah,
Rudén Ulla,
Hammarström Lennart,
Österborg Anders,
Wigzell Hans,
Mellstedt Håkan
Publication year - 2000
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2000.02307.x
Subject(s) - mhc class ii , immunology , monoclonal antibody , major histocompatibility complex , antibody , b cell , biology , complementarity determining region , mhc class i , t cell , antigen , immune system
We have previously shown that autologous T cells recognize leukaemic cells from patients with chronic lymphocytic leukaemia (B‐CLL) in an MHC class I‐ and/or II‐restricted manner. A candidate recognition structure might be the tumour cell‐derived Ig VH complementarity‐determining region (CDR)3. Three patients with B‐CLL were analysed for the presence of autologous T cells recognizing the tumour‐specific VH‐CDR3 region. The VH region was shown to be mutated in all three patients. In two patients, a VH‐CDR3‐specific T‐cell response was detected by proliferation assay, as well as by γ‐interferon (IFN) production. The responses could be inhibited by monoclonal antibodies against MHC class II, but not MHC class I. In the third patient, a VH‐CDR3 proliferative response was detected, which could be inhibited by an anti‐MHC class I monoclonal antibody, but not by anti‐MHC class II antibodies. No γ‐IFN response could be detected in this patient. In no patient was an interleukin (IL)‐4 response noted. Thus, in patients with B‐CLL, naturally occurring T cells recognizing the tumour‐unique VH‐CDR3 region are present.